Agios Pharmaceuticals, Inc.
AGIO
$34.41
-$1.09-3.07%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -18.68% | 19.70% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -18.68% | 19.70% | |||
| Cost of Revenue | -12.18% | 14.79% | |||
| Gross Profit | 11.23% | -14.11% | |||
| SG&A Expenses | -19.67% | 34.15% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -15.03% | 21.46% | |||
| Operating Income | 14.72% | -21.62% | |||
| Income Before Tax | 15.28% | -110.53% | |||
| Income Tax Expenses | -- | -116.71% | |||
| Earnings from Continuing Operations | 7.49% | -110.18% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 7.49% | -110.18% | |||
| EBIT | 14.72% | -21.62% | |||
| EBITDA | 14.81% | -21.88% | |||
| EPS Basic | 8.07% | -110.15% | |||
| Normalized Basic EPS | 15.81% | -19.30% | |||
| EPS Diluted | 8.07% | -110.42% | |||
| Normalized Diluted EPS | 15.81% | -22.42% | |||
| Average Basic Shares Outstanding | 0.63% | 0.29% | |||
| Average Diluted Shares Outstanding | 0.63% | -2.28% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||